Skip to main content

Table 3 Selected blood chemistry parameters mean values for healthy Beagle dogs treated with enflicoxib orally once a week for up to 7 months (SD)

From: Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months

Treatment group   0X 1X 3X 5X  
Dose (loading+maintenance)   (Placebo) (8 + 4 mg/kg) (24 + 12 mg/kg) (40 + 20 mg/kg) Pa
Alkaline phosphatase (U/L) Basal 73 (24) 65 (11) 63 (9) 60 (15) ns
(ALP) Week 4 103 (46) 70 (16) 86 (37) 88 (27) ns
  Week 8 95 (35) 74 (19) 87 (32) 125 (39) ns
  Week 13 99 (34) 74 (23) 88 (34) 95 (18) ns
  Week 17 97 (34) 75 (25) 86 (31)   ns
  Week 21 95 (41) 77 (26) 87 (40)   ns
  Week 25 88 (34) 69 (28) 85 (33)   ns
  Week 30 86 (41) 76 (31) 84 (37)   ns
Alanine aminotransferase (U/L) Basal 24 (7) 24 (6) 32 (17) 30 (9) ns
(ALT) Week 4 27 (6) 30 (6) 30 (5) 33 (8) ns
  Week 8 30 (6) 30 (6) 30 (6) 31 (7) ns
  Week 13 35 (11) 35 (8) 37 (4) 39 (10) ns
  Week 17 35 (11) 33 (6) 35 (7)   ns
  Week 21 30 (9) 31 (5) 34 (7)   ns
  Week 25 30 (8) 32 (8) 35 (7)   ns
  Week 30 35 (10) 33 (6) 35 (7)   ns
Aspartate aminotransferase (U/L) Basal 34 (7) 30 (6) 32 (5) 34 (6) ns
(AST) Week 4 36 (9) 34 (4) 37 (6) 39 (11) ns
  Week 8 34 (7) 32 (3) 34 (6) 34 (6) ns
  Week 13 40 (8) 35 (5) 48 (5) 40 (6) ns
  Week 17 41 (10) 37 (5) 39 (9)   ns
  Week 21 35 (6) 36 (4) 38 (6)   ns
  Week 25 35 (5) 35 (6) 42 (7)   ns
  Week 30 37 (8) 39 (5) 42 (5)   ns
Urea (mmol/L) Basal 5,5 (0,7) 5,5 (0,6) 5,8 (1,1) 5,5 (0,8) ns
  Week 4 5,8 (0,9) 6,4 (0,9) 7,4 (1,0) 7,9 (1,7)*  
  Week 8 5,8 (1,1) 6,5 (1,3) 7,3 (1,0) 8,3 (1,8)*  
  Week 13 4,6 (0,7) 5,0 (0,5) 6,0 (0,9)* 6,9 (0,9)**  
  Week 17 6,4 (0,8) 7,3 (1,3) 8,4 (2,1)*   
  Week 21 6,3 (1,2) 6,1 (0,9) 7,4 (0,9)   ns
  Week 25 5,7 (0,6) 6,3 (1,0) 7,2 (1,3)*   
  Week 30 5,4 (0,7) 6,5 (0,8) 7,2 (1,2)**   
Creatinine (μmol/L) Basal 51 (6) 52 (7) 59 (8) 58 (7) ns
  Week 4 54 (3) 54 (5) 58 (7) 59 (6) ns
  Week 8 53 (9) 56 (5) 58 (7) 60 (6) ns
  Week 13 54 (4) 50 (10) 55 (9) 60 (8) ns
  Week 17 54 (4) 51 (7) 55 (9)   ns
  Week 21 56 (7) 53 (7) 59 (10)   ns
  Week 25 53 (3) 53 (7) 57 (7)   ns
  Week 30 60 (4) 58 (6) 63 (10)   ns
Total Protein (g/L) Basal 55 (3) 54 (2) 55 (3) 54 (1) ns
  Week 4 57 (3) 54 (3) 53 (4) 52 (2) ns
  Week 8 53 (3) 53 (2) 51 (3) 51 (2) ns
  Week 13 58 (3) 54 (3) 55 (2) 54 (1) ns
  Week 17 57 (3) 54 (1) 53 (3)   ns
  Week 21 56 (3) 54 (3) 52 (3)   ns
  Week 25 58 (2) 56 (3) 53 (3)   ns
  Week 30 58 (2) 55 (4) 53 (3)   ns
Albumin (g/L) Basal 32 (2) 32 (1) 32 (2) 32 (2) ns
  Week 4 32 (2) 31 (1) 30 (2) 30 (2) ns
  Week 8 32 (1) 32 (2) 31 (2) 30 (1) ns
  Week 13 34 (2) 31 (2) 32 (2) 32 (1) ns
  Week 17 33 (2) 32 (2) 33 (2)   ns
  Week 21 33 (1) 32 (2) 31 (2)   ns
  Week 25 32 (1) 31 (2) 30 (2)   ns
  Week 30 34 (1) 32 (2) 31 (2)   ns
Cholesterol (mmol/L) Basal 3,6 (0,6) 4,0 (0,5) 3,3 (0,4) 3,5 (0,4) ns
  Week 4 4,3 (0,5) 4,9 (0,9) 4,4 (0,7) 5,1 (0,8) ns
  Week 8 4,0 (0,6) 4,8 (0,7) 4,4 (0,7) 5,4 (1,4) ns
  Week 13 4,1 (0,6) 4,4 (0,7) 5,1 (1,2)* 5,5 (1,1)**  
  Week 17 3,5 (0,6) 3,9 (0,6) 4,4 (1,0)   ns
  Week 21 4,2 (0,9) 4,8 (0,8) 4,6 (0,7)   ns
  Week 25 4,4 (0,9) 4,7 (0,9) 4,4 (0,7)   ns
  Week 30 3,9 (0,7) 4,7 (1,3) 4,6 (0,7)   ns
  1. aTreated groups compared with 0X group using Williams’ test (ns: p > 0.05, * p < 0.05, ** < 0.01)
  2. N = 4 animals/sex/treatment group